Elucid Stock

www.elucid.com/Healthcare / Healthcare softwareFounded: 2009

Elucid is a diagnostic imaging company that uses artificial intelligence to improve vascular patient outcomes. With a mission to prevent cardiovascular disease and improve pathology accuracy, Elucid optimizes clinical precision with arterial plaque analysis. Elucid also features ct angiography, FFRct, plaque characterization, and non-coding transcripts. Elucid was founded by Andrew J. Buckler in 2013 and is headquartered in Boston, MA.

Register To Buy and Sell Shares

For more details on financing and valuation for Elucid, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Elucid’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Elucid.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Elucid investors also invested in these private companies

Global Health Investment Fund
Elevage Medical Technologies
Aphelion Capital
Biovision Ventures
Philips Ventures
BlueStone Venture Partners
Bold Brain Ventures
Ice Age Gold
MedTex Ventures
Willamette Valley Capital
University of Michigan Endowment

Team

Management Team

Blake Richards
Chief Executive Officer
Andrew Miller
Chief Technology Officer & Senior Vice President Engineering
Scott Burger
Chief Commercial Officer
James Hamilton Ph.D
Co-Founder
Andrew Buckler
Co-Founder
Todd Villines
Chief Medical Officer

Board Members

Evan Melrose MD
Elevage Medical Technologies
Kelly Huang Ph.D
Elevage Medical Technologies

Elucid’s stock FAQs

plusminus

Can you buy Elucid’s stock?

Elucid is not publicly traded on NYSE or NASDAQ in the U.S. To buy Elucid’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Elucid’s stock?

Yes, you can sell stock of a private company like Elucid. Forge can help you sell your Elucid stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus

What is Elucid’s stock price?

Elucid is a privately held company and therefore does not have a public stock price. However, you may access Elucid’s private market stock price with Forge Data.
plusminus

What is Elucid’s stock ticker symbol?

Elucid does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Elucid collects $80M for AI-powered mapping of blocked arteries

The cardiovascular imaging company Elucid has made it clear they mean to deliver on their promise of artificial intelligence-powered exams to chart the insides of blocked arteries. And now they’ve raised $80 million to do so. Financially speaking, the startup has kept up its momentum since last year’s venture capital fundraising—with a $27 million series B in June 2022, which just about tripled its $8 million round from the year before. The most recent series C continues that trajectory, for a total of $121 million since Elucid’s founding.

Elucid scores $80M for AI imaging analysis software and more digital health fundings

AI company Elucid had a series C funding round which raised $80 million.
Updated on: Jul 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.